NasdaqCM - Nasdaq Real Time Price • USD
Vincerx Pharma, Inc. (VINC)
As of 3:57 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.23 | -0.22 | -1.02 | -0.94 |
| Low Estimate | -0.26 | -0.27 | -1.31 | -1.11 |
| High Estimate | -0.21 | -0.18 | -0.74 | -0.77 |
| Year Ago EPS | -0.68 | -0.52 | -1.89 | -1.02 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.52 | -0.6 | -0.46 | -0.37 |
| EPS Actual | -0.68 | -0.52 | -0.46 | -0.23 |
| Difference | -0.16 | 0.08 | 0 | 0.14 |
| Surprise % | -30.80% | 13.30% | 0.00% | 37.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.23 | -0.22 | -1.02 | -0.94 |
| 7 Days Ago | -0.23 | -0.22 | -1.02 | -0.94 |
| 30 Days Ago | -0.29 | -0.2 | -0.85 | -0.77 |
| 60 Days Ago | -0.19 | -0.16 | -0.58 | -0.76 |
| 90 Days Ago | -0.19 | -0.16 | -0.58 | -0.76 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VINC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 66.20% | -- | -- | 6.50% |
| Next Qtr. | 57.70% | -- | -- | 12.00% |
| Current Year | 46.00% | -- | -- | 5.30% |
| Next Year | 7.80% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 4/9/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 4/1/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/7/2023 |
| Maintains | Chardan Capital: Buy | 11/17/2022 |
| Maintains | SVB Leerink: Outperform | 8/12/2022 |
| Maintains | Cantor Fitzgerald: Overweight | 6/8/2022 |
Related Tickers
ELEV Elevation Oncology, Inc.
3.6200
-0.69%
EFTR eFFECTOR Therapeutics, Inc.
1.9300
+6.82%
RLYB Rallybio Corporation
1.7000
+3.03%
DAWN Day One Biopharmaceuticals, Inc.
14.90
+12.76%
ABEO Abeona Therapeutics Inc.
3.3000
+3.45%
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0100
+1.01%
CLRB Cellectar Biosciences, Inc.
3.0550
+1.16%
MRNS Marinus Pharmaceuticals, Inc.
1.4100
-0.70%
LPTX Leap Therapeutics, Inc.
3.1950
+0.79%
SPRB Spruce Biosciences, Inc.
0.7004
-0.09%